ArticleBMC cancer2016
Phase-specific and lifetime costs of cancer care in Ontario, Canada.
Article in BMC cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Prevalence and determinants of financial toxicity in patients with colorectal cancer: a systematic review and meta-analysis.International journal for equity in health · 2026Pooled it
- DNA Methylation-Based Classification for Central Nervous System Tumours: A Health Technology Assessment.Ontario health technology assessment series · 2025Pooled it
- Cost-of-Illness of Skin Cancer: A Systematic Review.PharmacoEconomics · 2024Pooled it
- Association between diabetic control and progression of monoclonal gammopathy of undetermined significance to multiple myeloma.Blood cancer journal · 2026Article
- Quantifying the contribution of modifiable risk factors for progression of MGUS to multiple myeloma in a Veteran population.International journal of cancer · 2026Article
- Healthcare costs and resource use in advanced breast cancer at the end of life: a register study.Acta oncologica (Stockholm, Sweden) · 2026Article
- Overestimation of multiple myeloma survival from cancer registry data.Journal of the National Cancer Institute · 2026Article
- Testicular Cancer: Diagnosis, Treatment, and Biomarker Advances.Research and reports in urology · 2026Review
- Economic burden of cancer care in Lebanon's privately insured population: a seven-year retrospective cohort analysis (2018-2024).Frontiers in oncology · 2026Article
- Short- and Long-Term Healthcare Costs Attributable to Hepatitis B Among Newcomers to Ontario, Canada: A Matched Cohort Study.Canadian journal of gastroenterology & hepatology · 2026Article
- Palliative Care With Tracheostomy or Gastrostomy Tube Use and End-of-Life Quality and Costs Among Patients With Head and Neck Cancer.JAMA otolaryngology-- head & neck surgery · 2025Article
- Cost-Effectiveness Analysis of Contemporary Advanced Prostate Cancer Treatment Sequences.Current oncology (Toronto, Ont.) · 2025Article
- Addressing immortal time bias in precision medicine: Practical guidance and methods development.Health services research · 2025Article
- Net Health System Costs of Parkinson Disease: A Propensity Score-Matched Health Administrative Data Cohort Study in Ontario, Canada.Neurology. Clinical practice · 2025Article
- Insights from GoFundMe posts: Analyzing GoFundMe financial aid requests from brain tumor patients in Ontario, Canada.Neuro-oncology practice · 2025Article
- Healthcare Resource Utilization and Associated Costs During the First 5 Years After Diagnosis and at the End of Life: A Nationwide Cohort Study of Patients with Multiple Myeloma in Finland.PharmacoEconomics - open · 2025Article
- Implementing a smoke-free generation policy for Canada: estimates of the long-term impacts.Health promotion and chronic disease prevention in Canada : research, policy and practice · 2025Article
- Article
- Differences in Health Care Expenditures by Cancer Patients During Their Last Year of Life: A Registry-Based Study.Current oncology (Toronto, Ont.) · 2024Article
- The Economic Impact of Treatment Sequencing in Chronic Lymphocytic Leukemia in Canada Using Venetoclax plus Obinutuzumab.Cancers · 2024Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer is a major public health issue and represents a significant economic burden to health care systems worldwide. The objective of this analysis was to estimate phase-specific, 5-year and lifetime net costs for the 21 most prevalent cancer sites, and remaining tumour sites combined, in Ontario, Canada.
methodsWe selected all adult patients diagnosed with a primary cancer between 1997 and 2007, with valid ICD-O site and histology codes, and who survived 30 days or more after diagnosis, from the Ontario Cancer Registry (N = 394,092). Patients were linked to treatment data from Cancer Care Ontario and administrative health care databases at the Institute for Clinical and Evaluative Sciences. Net costs (i.e., cost difference between patients and matched non-cancer control subjects) were estimated by phase of care and sex, and used to estimate 5-year and lifetime costs.
resultsMean net costs of care (2009 CAD) were highest in the initial (6 months post-diagnosis) and terminal (12 months pre-death) phases, and lowest in the (3 months) pre-diagnosis and continuing phases of care. Phase-specific net costs were generally lowest for melanoma and highest for brain cancer. Mean 5-year net costs varied from less than $25,000 for melanoma, thyroid and testicular cancers to more than $60,000 for multiple myeloma and leukemia. Lifetime costs ranged from less than $55,000 for lung and liver cancers to over $110,000 for leukemia, multiple myeloma, lymphoma and breast cancer.
conclusionsCosts of cancer care are substantial and vary by cancer site, phase of care and time horizon analyzed. These cost estimates are valuable to decision makers to understand the economic burden of cancer care and may be useful inputs to researchers undertaking cancer-related economic evaluations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.